The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review

Ning, Xian‐Gu; Yu, Yang; Shao, Songjun; Deng, Rong; J, Yu; Wang, Xüming; She, Xueke; Huang, Depei; Shen, Xudong; Duan, Weiming; Duan, Jian; Zhang, Hushan

doi:10.21037/atm-21-4878

Cited by 16 publications

(12 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were excluded if they had any missing values for race, ethnicity, or any other study variables ( Figure 1 ). The third edition of the International Classification of Diseases for Oncology (ICD-O) codes was used to identify cases of NSCLC, based on the primary site of the cancer, its morphology, and behavior ( Table S1 ) ( 30 , 32 ).…”

Section: Methodsmentioning

confidence: 99%

“…Patient’s smoking history and clinical characteristics such as cancer stage were also identified and defined at baseline. Immunotherapy is commonly administered with other agents, especially chemotherapy ( 29 , 32 ), so receipt of other treatment modalities as first-line agents such as chemotherapy, radiotherapy, hormone therapy, and surgery were also measured.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study

et al. 2023

View full text Add to dashboard Cite

BackgroundThe use of immunotherapy is associated with improved survival among patients with Non-Small Cell Lung Cancer (NSCLC) and has gained widespread use in its management. However, there is limited information on whether the survival benefits associated with immunotherapy differ among races and ethnicities.ObjectiveThis study aimed to investigate racial differences in survival amongst patients with NSCLC who received immunotherapy as the first-line treatment in Texas.MethodsPatients with NSCLC who received immunotherapy between October 2015 to December 2018 were identified from the Texas Cancer Registry (TCR). Disease-specific survival was evaluated and compared among patients across racial/ethnic categories using the Kaplan-Meier survival analysis, log-rank test, and a multivariable Cox proportional hazard regression model following an inverse probability treatment weighting (IPTW) propensity score analysis.ResultsA total of 1453 patients were included in the analysis. Median survival (in months) was longest among Asians (34, 95% CI: 15-Not Estimable), followed by African Americans (AAs) (23, 95% CI: 15-34), Hispanics (22, 95% CI: 16-26), and Whites (19, 95% CI: 17-22). The adjusted regression estimates had no statistically significant differences in survival among AAs (aHR = 0.97; 95% CI = 0.78-1.20; P =0.77) and Hispanics (aHR = 0.96; 95% CI = 0.77-1.19, P =0.73) when compared to White patients. Asians on the other hand, had 40% reduction in mortality risk compared to Whites (aHR = 0.60; 95% CI = 0.39-0.94, P = 0.03).ConclusionsOur study indicated that African Americans and Hispanics do not have poorer survival compared to White patients when receiving immunotherapy as first-line treatment. Asians however had longer survival compared to Whites. Our findings suggest that existing racial disparity in NSCLC survival might be mitigated with the use of immunotherapy and should be considered in providing care to these minority groups.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…15,16 Treatment options for lung cancer can be applied alone or in combination and include surgery (for early stage disease), chemotherapy, radiotherapy, targeted therapy, and immunotherapy. [17][18][19][20][21] Despite recent advances in the diagnosis and treatment of lung cancer, the prognosis is still unfavorable. According to the tumor-node-metastasis (TNM)-based staging of lung cancer, the 5-year survival rate for NSCLC varies between 50% in clinical stage IA and 2% in clinical stage IV.…”

Section: Introductionmentioning

confidence: 99%

New biochemical, immune and molecular markers in lung cancer: Diagnostic and prognostic opportunities

2022

View full text Add to dashboard Cite

Lung cancer is one of the most common neoplasms and the leading cause of cancer-related deaths worldwide. Despite recent progress in understanding the pathomechanisms of lung cancer, it is frequently associated with late diagnosis, high incidence of metastases and poor response to treatment. Thus, there is extensive research in the field of biomarkers that aims to optimize management of lung cancer. The aim of this study was to review the current perspectives of a wide spectrum of circulating molecules that seem promising as new potential biomarkers of lung cancer. Among these, biochemical (active proteins), immunological (immunocompetent cells, cytokines, chemokines, and antibodies) and genetic (circulating tumor DNA, cell-free DNA and microRNA) markers are presented and discussed. The use of these markers would support the early detection of lung cancer and might be used for predicting disease progression, response of the disease to targeted therapies, monitoring the course of treatment, and developing individualized diagnostic and therapeutic strategies. Special attention was given to potential markers of nervous system involvement in the course of lung cancer, due to its prevalence and devastating impact. Limitations of the potential biomarkers are also outlined and future directions of investigations in this field highlighted, with the aim of improving the accuracy and practical utility of these biomarkers.

show abstract

“…Many chemoimmunotherapy regimens have now been approved by the FDA for use in cancer therapy and many others are being investigated in clinical studies [4]. Despite the great success of cancer chemoimmunotherapy, it has not been able to achieve long-lasting therapeutic bene ts for patients [5,6]; therefore, additional strategies are still needed for the majority of cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Synergistic Effects of HIF-1α Inhibition, Toll-Like Receptor 7 Agonist, and Chemotherapy in Mice Model of Colon Cancer

Rostamizadeh

Ramazani

Monirinasab

et al. 2022

Preprint

View full text Add to dashboard Cite

Recently, combination therapies have become a promising option with hopeful therapeutic outcomes due to their strong antitumor effects. Among them, despite the great success of cancer chemoimmunotherapy, it has not been able to improve the outcome of patients. Immunosuppressive tumor microenvironment (TME) has been recognized as the main barrier to immunotherapy. So, it has been assumed that targeting HIF-1α as a reshaping of TME combined with chemoimmunotherapy can capably enhance the antitumor response of therapy. Herein, we have studied the therapeutic effects of HIF-1α inhibition combined with chemoimmunotherapy. We established CT26 mouse models to assess the synergistic effect of genetic silencing of HIF-1α combined with oxaliplatin (OXA) and imiquimod (IMQ) on tumor growth and TME. We showed that in comparison with dual combination therapy, mice treated with triple combination therapy exhibited a significant delay in tumor growth, which was correlated with high levels of cellular immune-related cytokines. Besides, mice without HIF-1α siRNA treatment exhibited high tumor growth and high levels of immunosuppressive factors, indicating an immunosuppressive phenotype. Briefly, we found that HIF-1α inhibition could synergize with OXA and IMQ to inhibit tumor growth in vivo. Our data suggest that targeting HIF-1α represents a promising strategy to enhance the antitumor response of chemoimmunotherapy.

show abstract

The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review

Cited by 16 publications

References 46 publications

Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study

Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study

New biochemical, immune and molecular markers in lung cancer: Diagnostic and prognostic opportunities

Synergistic Effects of HIF-1α Inhibition, Toll-Like Receptor 7 Agonist, and Chemotherapy in Mice Model of Colon Cancer

Contact Info

Product

Resources

About